Under the deal, BeiGene will help Amgen commercialize its oncology drugs in China, while Amgen will acquire slightly more than one-fifth of the Beijing-based firm. BeiGene will also participate in R&D efforts on 20 drugs in Amgen's oncology portfolio.
CAR-Ts have generated excitement, but bispecific monoclonal antibodies may continue to have a competitive edge in some cases.
Finding the best analytics tools for health care revenue management can revolutionize operational processes. Compare the leading software options to discover helpful team resources.
Lava Therapeutics nets 16 million euros in Series B round and plans to decide on clinical drug candidate in oncology this year.